Q3 catalysts podcast: Evaluate Vantage hits the airwaves

Got time for a quick brain break? Listen to our podcast where we discuss the catalysts that will shape the third quarter of 2022.

The third quarter of 2022 is upon us and to celebrate, Evaluate Vantage is launching its first podcast! In this short session, Lisa Urquhart and I discuss upcoming catalysts, looking at what’s happening with big pharma, interesting biotechs and some of the minnows who are playing with the big boys. We look at the battleground in the infant pneumococcal vaccine market, whether companies are simply throwing good money after bad in Alzheimers, and what’s on the horizon for novel eye drugs with a significant patent expiry coming up next year.

If you’d like to know more about the topics we discuss (including a late breaking Nash update since the recording!) there are links below to point you in the right direction. 




Need to know more? Here are the articles we talk about in the podcast.

Industry trends

Share This Article